SkinBioTherapeutics (LON:SBTX) Stock Price Down 10.5% – Time to Sell?

SkinBioTherapeutics plc (LON:SBTX – Get Free Report)’s share price dropped 10.5% during trading on Wednesday. The stock traded as low as GBX 4 and last traded at GBX 4.25. 1,153,087 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 2,500,853 shares. The stock had previously closed at GBX 4.75.

SkinBioTherapeutics Stock Down 15.7%

The business’s 50 day moving average is GBX 6.09 and its 200 day moving average is GBX 9.39. The company has a market capitalization of £10.38 million, a price-to-earnings ratio of -25.03 and a beta of 0.10. The company has a debt-to-equity ratio of 11.77, a quick ratio of 10.01 and a current ratio of 6.14.

SkinBioTherapeutics Company Profile

(Get Free Report)

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.

Further Reading

Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.